Alnylam Pharmaceuticals, Inc. (LON: 0HD2)

London flag London · Delayed Price · Currency is GBP · Price in USD
244.60
+5.26 (2.20%)
Dec 20, 2024, 5:22 PM BST
29.44%
Market Cap 25.18B
Revenue (ttm) 1.56B
Net Income (ttm) -247.90M
Shares Out n/a
EPS (ttm) -1.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 70
Open 239.50
Previous Close 239.33
Day's Range 236.45 - 244.60
52-Week Range 143.66 - 244.60
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Feb 20, 2025

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the... [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 2002
Employees 2,100
Stock Exchange London Stock Exchange
Ticker Symbol 0HD2
Full Company Profile

Financial Performance

In 2023, Alnylam Pharmaceuticals's revenue was $1.83 billion, an increase of 76.23% compared to the previous year's $1.04 billion. Losses were -$440.24 million, -61.08% less than in 2022.

Financial numbers in USD Financial Statements

News

$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today

Alnylam Pharmaceuticals (NASDAQ: ALNY) has outperformed the market over the past 20 years by 11.51% on an annualized basis producing an average annual return of 19.9%. Currently, Alnylam Pharmaceutic...

13 days ago - Benzinga

Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Piper San...

26 days ago - Business Wire

Check Out What Whales Are Doing With ALNY

Financial giants have made a conspicuous bearish move on Alnylam Pharmaceuticals. Our analysis of options history for Alnylam Pharmaceuticals (NASDAQ: ALNY) revealed 19 unusual trades. Delving into t...

27 days ago - Benzinga

Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has accepted fo...

4 weeks ago - Business Wire

Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the presentation of new results from its Phase 1 study of nucres...

5 weeks ago - Business Wire

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following ...

7 weeks ago - Business Wire

Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2024 Earnings Call Transcript

Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2024 Earnings Call Transcript

7 weeks ago - Seeking Alpha

Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended Se...

7 weeks ago - Business Wire

Alnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present data from its transthyretin amyloi...

7 weeks ago - Business Wire

Alnylam Pharmaceuticals Q3 Earnings Preview: Key RNAi Catalysts To Watch

Alnylam Pharmaceuticals is a leader in RNAi therapeutics, with multiple FDA-approved treatments and a robust pipeline targeting rare and severe conditions. The company has strong growth potential, par...

2 months ago - Seeking Alpha

Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter endi...

2 months ago - Business Wire

Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced the submission of a Type II Variation to the ...

2 months ago - Business Wire

Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the submission of its supplemental New Drug Application (sNDA) t...

2 months ago - Business Wire

Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that two new data sets from the HELIOS-B Phase 3 study of vutris...

3 months ago - Business Wire

Alnylam to Webcast TTR Investor Day

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Day event on the ...

3 months ago - Business Wire

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly

Sometimes obscure diseases represent large opportunities for drug companies.

3 months ago - WSJ

Steward Health Care and Medical Properties Trust Reach Settlement Agreement in Principle, Allowing for Steward-Operated Hospitals to Be Transitioned to New Ownership

DALLAS--(BUSINESS WIRE)--Steward Health Care (“Steward”), the country's largest physician-led, minority-owned, integrated health care system, announced today it has reached an agreement in principle w...

4 months ago - Business Wire

Alnylam: HELIOS-B Success Priced In Already

Alnylam's stock surged due to positive HELIOS-B trial results, but lacked additional upside today after the company presented the data at the ESC congress. Amvuttra shows competitive efficacy and safe...

4 months ago - Seeking Alpha

Kern Subbasin Groundwater Sustainability Agencies Urge State to Consider Updated Plan

BAKERSFIELD, Calif.--(BUSINESS WIRE)--The Kern Subbasin Groundwater Sustainability Agencies (GSAs) have responded to a draft report from the California State Water Resources Control Board (SWRCB). The...

4 months ago - Business Wire

Alnylam Pharmaceuticals Stock Falls After Detailed Vutrisiran Data For A Condition With Stiff Heart Muscles

Friday, Alnylam Pharmaceuticals Inc. ALNY stock is trading lower after the company shared detailed results from the HELIOS-B Phase 3 study of vutrisiran for ATTR amyloidosis with cardiomyopathy (ATTR-...

4 months ago - Benzinga

Alnylam shares slide after heart drug data fails to impress investors

Alnylam Pharmaceuticals' shares fell nearly 11% before the bell on Friday, after data for its closely watched heart drug fell short of heightened investor expectations.

4 months ago - Reuters

Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced detailed results from the HELIOS-B Phase 3 study of vutrisiran, ...

4 months ago - Business Wire

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following ...

4 months ago - Business Wire

Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present results from the HELIOS-B Phase 3 ...

4 months ago - Business Wire

Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2024 Earnings Call Transcript

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q2 2024 Earnings Conference Call August 1, 2024 8:00 AM ET Company Participants Christine Lindenboom - SVP, IR and Corporate Communications Yvonne Greenstr...

5 months ago - Seeking Alpha